Sandoz and Polpharma Biologics did not immediately reveal their launch or pricing plans, but the National MS Society said it expected the drug to be ... main patents on Tysabri (natalizumab ...

Another case of a potentially fatal brain infection has been reported in a patient taking the multiple sclerosis drug Tysabri, the biotech who developed the drug announced yesterday. This is the ...

The looming competition piles further pressure on Biogen, whose MS franchise is already ... Tecfidera's decline has made Tysabri Biogen's top-selling drug. Last year, Polpharma Biologics and ...

Cumulative lifetime dose limit Secondary progressive, progressive relapsing, or worsening RRMS Tysabri® Natalizumab ... Current MS disease-modifying drugs primarily target the inflammatory ...

Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has ...